Search

Your search keyword '"Chatterjee, Saswati"' showing total 15 results
Start Over Author "Chatterjee, Saswati" Publication Year Range Last 10 years
15 results on '"Chatterjee, Saswati"'

1. An Outline of Cyber-Physical System: Issues and Security Risks

Author

Benzer, Noel Job, Vishnu, Aditya, Chatterjee, Saswati, Satpathy, Suneeta, Chakrabarti, Amlan, Series Editor, Becker, Jürgen, Editorial Board Member, Hu, Yu-Chen, Editorial Board Member, Chattopadhyay, Anupam, Editorial Board Member, Tribedi, Gaurav, Editorial Board Member, Saha, Sriparna, Editorial Board Member, Goswami, Saptarsi, Editorial Board Member, Sharma, Nonita, editor, Mangla, Monika, editor, and Shinde, Subhash K., editor

Published
2024
Full Text
View/download PDF

2. An Intrusion Detection System and Attack Intension Used in Network Forensic Exploration

Author

Chatterjee, Saswati, Pattnaik, Lal Mohan, Satpathy, Suneeta, Akan, Ozgur, Editorial Board Member, Bellavista, Paolo, Editorial Board Member, Cao, Jiannong, Editorial Board Member, Coulson, Geoffrey, Editorial Board Member, Dressler, Falko, Editorial Board Member, Ferrari, Domenico, Editorial Board Member, Gerla, Mario, Editorial Board Member, Kobayashi, Hisashi, Editorial Board Member, Palazzo, Sergio, Editorial Board Member, Sahni, Sartaj, Editorial Board Member, Shen, Xuemin, Editorial Board Member, Stan, Mircea, Editorial Board Member, Jia, Xiaohua, Editorial Board Member, Zomaya, Albert Y., Editorial Board Member, Nandan Mohanty, Sachi, editor, Garcia Diaz, Vicente, editor, and Satish Kumar, G. A. E., editor

Published
2023
Full Text
View/download PDF

5. Sources and Security Issues in Terahertz Technologies

Author

Chatterjee, Saswati, Angrisani, Leopoldo, Series Editor, Arteaga, Marco, Series Editor, Panigrahi, Bijaya Ketan, Series Editor, Chakraborty, Samarjit, Series Editor, Chen, Jiming, Series Editor, Chen, Shanben, Series Editor, Chen, Tan Kay, Series Editor, Dillmann, Rüdiger, Series Editor, Duan, Haibin, Series Editor, Ferrari, Gianluigi, Series Editor, Ferre, Manuel, Series Editor, Hirche, Sandra, Series Editor, Jabbari, Faryar, Series Editor, Jia, Limin, Series Editor, Kacprzyk, Janusz, Series Editor, Khamis, Alaa, Series Editor, Kroeger, Torsten, Series Editor, Liang, Qilian, Series Editor, Martín, Ferran, Series Editor, Ming, Tan Cher, Series Editor, Minker, Wolfgang, Series Editor, Misra, Pradeep, Series Editor, Möller, Sebastian, Series Editor, Mukhopadhyay, Subhas, Series Editor, Ning, Cun-Zheng, Series Editor, Nishida, Toyoaki, Series Editor, Pascucci, Federica, Series Editor, Qin, Yong, Series Editor, Seng, Gan Woon, Series Editor, Speidel, Joachim, Series Editor, Veiga, Germano, Series Editor, Wu, Haitao, Series Editor, Zhang, Junjie James, Series Editor, Acharyya, Aritra, editor, and Das, Palash, editor

Published
2021
Full Text
View/download PDF

9. Intensified Production of Vaccinia-Based Oncolytics in the High Density Cell Respirator (HDCR) Bioreactor Improves Vaccine Logistics and Economics

Author

Cook, Colin A., Kang, Seonah, Lu, Jianming, Tai, Yu-Chong, Chatterjee, Saswati, and Fong, Yuman

Abstract

Intensification of cell-based production processes is key to improving oncolytic vaccine logistics and economics by saving on GMP space, time, labor, and feedstock. Many promising vectors, including those based on vaccinia virus (e.g. CF33, JX-594/Pexa-Vec) are still produced using flask-based culture due to the cost, effort, and uncertainty involved in adapting to stirred-tank or perfusion processes. Based on prior success culturing adherent cells (e.g. HEK293, A549, CV-1) to high densities (107-8 cells/mL) using the scalable high-density cell respirator (HDCR) bioreactor, we hypothesized that the platform could support orders-of-magnitude-intensified production of replication competent viruses. Here we report on CF33 virus production as a proof-of-concept for oncolytic virotherapy. Bioreactor cartridges were produced based on a 4-stack of 600 cm² HDCR membranes, featuring a proprietary gas perfusable and permeable microarchitecture that optimally oxygenates cells even at high densities. Media perfusion was feedback-controlled based on glucose measurements in the waste stream. A549 cells were seeded into the bioreactor on microcarriers, expanded 10-fold to mid-10⁷ cells/mL densities, infected with CF33 virus (MOI of 0.1), and harvested 48 hours post-infection. CF33 virus was gradient purified and titered for functional virus by plaque forming assay. Multiple production runs using different strains of CF33 virus validated the reproducibility of the process, as summarized in Table 1. Importantly, cell specific titers (PFU/cell) remained comparable to conventional flask-based production, leading to significant intensification due to the higher cell densities supported in the HDCR bioreactor. Volumetric productivity is on the order of 100× that of cell factories. The efficient usage of media due to the gas-media decoupled operation of the HDCR bioreactor enables gradient-purified virus costs of around $500/1010 PFU. This is significantly below the $10,000/1010 PFU charged by CMOs and supports our mission of democratizing access to life saving medicines. The straightforward adaptation of CF33 virus production from a flask-based to a high yield, intensified process highlights the logistical and economical advantage of the HDCR platform for oncolytics.

Published
2021

11. A Tribute to Barrie J. Carter

Author

Srivastava, Arun, primary, Weitzman, Matthew, additional, Chatterjee, Saswati, additional, Engelhardt, John F., additional, Owens, Roland A., additional, Muzyczka, Nick, additional, and Ali, Robin, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results